Monoarthritis revealing Infliximab-induced systemic lupus erythematosus in Crohn's disease

Abstract

Infliximab, a chimeric monoclonal antibody, is an anti-tumor necrosis factor alpha (anti-TNFα) that is increasingly used for the treatment of severe and resistant forms of inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)).1,2 It is characterized by its efficiency and good tolerance.2 Induced systemic lupus erythematosus (SLE) remains an exceptional but potentially serious complication of this biological treatment.1,2